The embodiments disclose a method including functionalizing a biosensor with a biologic analytical target prior to installation into a detection cartridge, depositing a test subject bodily fluid test sample onto the biosensor surface, inserting the detection cartridge into a portable detection cartridge reader, measuring the electrical impedance of the bodily fluid test sample across biosensor energized electrodes, providing algorithms for analyzing measured electrical impedance data of the bodily fluid test sample obtained in the detection cartridge, identifying and determining the presence of biologic analytical target molecules in the bodily fluid test sample, and transmitting results of the test results to the test subject.

The present disclosure provides human antibodies and fragments thereof having binding specificity to the SARS-CoV-2 spike protein's receptor binding domain (RBD). The antibodies and fragments have strong affinity and potent neutralization ability against the SARS-CoV-2 virus and various mutant forms. Also provided are trimeric antibodies which have further enhanced neutralization capabilities. The antibodies and fragments thus may be used for preventing or treating SARS-CoV-2 viral infection or detecting the presence of the virus in a sample.

The present invention provides a packaging box, including a box body; the box body is provided with an insertable zone; a dashed hole is disposed at an edge of the insertable zone. The insertable zone is round and may be completely or partially separated from the box body; there is an insertable zone on the box body. The packaging box provided by the present invention has an insertable zone. The detecting personnel need not find out an extra tubular fixed seat for use. Meanwhile, a packaging box is used to replace a tubular fixed seat, reducing the use cost of the detecting apparatus. Moreover, each lysis tube can be inserted into respective packaging box; and each packaging box is corresponding to respective detecting apparatus. Therefore, it is not easy to cause the misuse of lysis tubes during loading and detection procedure, thereby avoiding wrong detection because the lysis tube is taken by mistake.

Detecting systems configured to detect airborne viruses, and methods of forming the same, are provide. A method for preparing a system for detecting an airborne virus includes preparing a thin-film coating on a surface of a substrate; ablating the coating to form an optical grating structure; and associating a plurality of receptors having an affinity and specificity for the virus with the optical grating structure so that the structure is capable of indicating the presence of the virus. A detecting system includes the optical grating structure and an optical component. The optical component includes a cavity defined by two opposing reflecting surfaces and configured to receive the optical grating structure, and a light source disposed adjacent to an exterior surface of a first reflecting surface. The light source may be configured to direct light towards the first reflecting surface so that light in resonance enters the cavity.

The invention provides a test kit and a test method using the same. The test kit utilized for detecting the neutralizing antibody against COVID-19 has high sensitivity and specificity. The test kit especially comprises antigen-complex that essentially consists of a receptor binding domain (RBD) located in COVID-19 spike glycoprotein, two N-terminal domains located in COVID-19 spike glycoprotein and a domain between the RBD and the N-terminal domain (NTD). The test kit may quantitatively determine the titer of the neutralizing antibody against COVID-19.

The present disclosure relates in some aspects to immunogenic compositions including recombinant peptides and proteins comprising coronavirus viral antigens and immunogens, e.g., coronavirus S protein peptides. In some aspects, the immunogenic composition comprises a secreted fusion protein comprising a soluble coronavirus viral antigen joined by in-frame fusion to a C-terminal portion of a collagen which is capable of self-trimerization to form a disulfide bond-linked trimeric fusion protein. In some aspects, the immunogenic compositions provided herein are useful for generating an immune response, e.g., for treating or preventing a coronavirus infection. In some aspects, the immunogenic compositions provided herein may be used in a vaccine composition, e.g., as part of a prophylactic and/or therapeutic vaccine. Also provided herein are methods for producing the recombinant peptides and proteins, prophylactic, therapeutic, and/or diagnostic methods, and related kits.

A method for detection and measurement of neutralizing antibody levels to SARS-CoV-2 in a test-specimen, said method comprising: obtaining a whole blood test-specimen from a subject; transferring the test-specimen to a sample well of a test-cassette, wherein the cassette further comprises a blood filter, a conjugate pad, a nitrocellulose membrane and an absorbent pad, wherein the sample pad comprises ACE2 or a functional fragment thereof, wherein the conjugate pad comprises a viral-ACE2-binding protein coupled to a label; adding a buffer; and reading the results from the test-cassette.

Methods, systems and devices for detecting the presence of a pathogen, for example, a virus (e.g., SARS-CoV-2), or its molecular components, in health care-related samples and/or environmental samples are disclosed. An example system for improving detection of a pathogen includes biosensor device comprising a detection chip and at least one probe that specifically recognizes a pathogen, where the detection chip comprises a graphene field-effect transistor (FET) chip and the probe, which comprises an aptamer, specifically binds to a DNA, RNA, or protein associated with the pathogen.

Embodiments may include a rapid test device that provide rapid detection of substances, including those involved in pathogen infection, for example, using Microscale Affinity Chromatography (MAC), indirect ELISA, and optical molecular sensing technology. For example, in an embodiment, a system may comprise a cartridge comprising a first chamber configured to receive a test sample including a target substance, the first chamber pre-filled with micromagnetic particles treated so as to bind to the target substance, and a first reservoir pre-filled with at least one reagent labeled with at least one fluorescent compound, the reagent adapted to bind to micromagnetic particles that are bound to the target substance, and an apparatus comprising a light source disposed so as to excite the least one fluorescent compound with a light and an optical sensor disposed so as to detect an emitted spectrum of light from the excited least one fluorescent compound.

An embodiment relates to a reagent buffer comprising a zwitterionic sulfonic solution, a non-ionic surfactant solution, and a buffer solution, wherein the reagent buffer has a pH range of about 7.0 to about 8.0 and a circular dichroism with an absorbance peak more than 0 at 190 nm and 225 nm. In an embodiment, the reagent buffer is configured to be a reagent buffer for a lateral flow immunoassay for detection of COVID-19.